We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanogen and Fisher to Collaborate in Molecular Diagnostics

By HospiMedica staff writers
Posted on 15 Aug 2006
Nanogen (San Diego, CA, USA) and Fisher Scientific (Hampton, NH, USA) have announced that the two companies have expanded their relationship to include a research-and-development collaboration in molecular diagnostics.

Nanogen and Fisher Scientific agreed to share technology and patent rights specifically for the development, manufacture, and marketing of new molecular diagnostic products. More...
Under the agreement, Fisher Scientific may provide up to U.S.$10 million in total during 2007 and 2008 for the research and development of infectious diseases and molecular diagnostic tests that will be mutually agreed upon. The companies believe that the extensive knowledge, intellectual property, and capabilities of both companies will enable molecular diagnostic products to be brought to the market more quickly. Additional details were not disclosed.

Nanogen and Athena Diagnostics, a wholly owned subsidiary of Fisher Scientific International, have agreed to develop, manufacture, and market products based on Athena's proprietary biomarkers for research and for in vitro diagnostic use. Athena has an extensive portfolio of unique markers in the fields of neurology and endocrinology that it has successfully incorporated into its testing service, several of which could be incorporated into assays for use on Nanogen's microarray platform, the NanoChip400. Nanogen also has access to a wide range of markers that could be used to create unique tests for the Athena Diagnostics testing service.

"We see tremendous opportunities in molecular diagnostics and are pleased to be expanding our presence in this rapidly growing market,” said Leland Foster, chief science officer for Fisher Scientific International. "By fostering a collaboration between Nanogen and Athena and furthering Nanogen's R&D efforts, we are advancing the abilities of both companies to bring diagnostic products to the marketplace.”

Nanogen's technologies provide researchers, clinicians, and physicians with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time polymerase chain reaction (PCR) reagents, the NanoChip electronic microarray platform, and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and has potential for diagnostic and biodefense applications.

Fisher Scientific facilitates discovery by supplying labs around the world with the tools they need, including biochemicals, cell-culture media, RNAi technology, and rapid diagnostic tests.



Related Links:
Nanogen
Fisher Scientific

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Thyroid Test
Anti-Thyroid EIA Test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.